<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01274975</url>
  </required_header>
  <id_info>
    <org_study_id>Astrostem</org_study_id>
    <nct_id>NCT01274975</nct_id>
  </id_info>
  <brief_title>Autologous Adipose Derived MSCs Transplantation in Patient With Spinal Cord Injury.</brief_title>
  <acronym>MSC</acronym>
  <official_title>Safety of Autologous Adipose Derived Mesenchymal Stem Cells in Patients With Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R-Bio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>R-Bio</source>
  <brief_summary>
    <textblock>
      This study is designed to assess the safety of intravenous autologous adipose derived&#xD;
      mesenchymal stem cells transplant in spinal cord injury patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adipose derived mesenchymal stem cells (AdMSCs) represent an attractive and ethical cell&#xD;
      source for stem cell therapy.&#xD;
&#xD;
      With the recent demonstration of MSC homing properties, intravenous aplications of MSCs to&#xD;
      cell-damaged diseases have increased.&#xD;
&#xD;
      In a human clinical trial, eight male patients who had suffered a spinal cord injury were&#xD;
      intravenously administered autologous hAdMSCs (4×10e8 cells) one time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety evaluation</measure>
    <time_frame>12weeks</time_frame>
    <description>Safety evaluate through physical examination, vital sign and laboratory test after &quot;RNL-Astrostem&quot; injected</description>
  </primary_outcome>
  <enrollment type="Actual">8</enrollment>
  <condition>Spinal Cord Injury</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous Adipose Derived Mesenchymal Stem Cells</intervention_name>
    <description>Intravenous infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4 x 10e8 cells</description>
    <other_name>Astrostem®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who understand and sign the consent form for this study.&#xD;
&#xD;
          -  Age :19-60, males&#xD;
&#xD;
          -  Clinical diagnosis of spinal cord injury(American Spinal Injury Association[ASIA]&#xD;
             Impairment Scale[AIS] grade A or B or C)&#xD;
&#xD;
          -  Duration of injury : &gt; 2 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who must put on a respirator&#xD;
&#xD;
          -  Subjects who had malignant tumor within 5 years&#xD;
&#xD;
          -  Subjects with a infectious disease include HIV and hepatitis&#xD;
&#xD;
          -  Subjects who injured brain or spinal cord before spinal cord injury&#xD;
&#xD;
          -  Subjects who has high body temperature more than 38℃ or acute disorder&#xD;
&#xD;
          -  Subjects with anemia or thrombocytopenia&#xD;
&#xD;
          -  Subjects with angina pectoris, myocardial infarction, cardiomyopathy, occlusive&#xD;
             disease, chronic renal failure, glomerular disease and chronic obstructive pulmonary&#xD;
             disease&#xD;
&#xD;
          -  Subjects with congenital or acquired immunodeficiency disorders&#xD;
&#xD;
          -  Subjects with muscular dystrophy or articular rigidity&#xD;
&#xD;
          -  Patients with clouded consciousness or speech disorder&#xD;
&#xD;
          -  treat with cytotoxic medications(immunosuppressive drug, corticosteroid and cytotoxic&#xD;
             drug) during clinical trials&#xD;
&#xD;
          -  participating another clinical trials within 3 months&#xD;
&#xD;
          -  other serious disease or disorder that could seriously affect ability to participate&#xD;
             in the study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SangHan Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anyang Sam Hospital</affiliation>
  </overall_official>
  <results_reference>
    <citation>Ra JC, Shin IS, Kim SH, Kang SK, Kang BC, Lee HY, Kim YJ, Jo JY, Yoon EJ, Choi HJ, Kwon E. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev. 2011 Aug;20(8):1297-308. doi: 10.1089/scd.2010.0466. Epub 2011 Mar 17.</citation>
    <PMID>21303266</PMID>
  </results_reference>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>January 6, 2011</study_first_submitted>
  <study_first_submitted_qc>January 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2011</study_first_posted>
  <last_update_submitted>March 24, 2014</last_update_submitted>
  <last_update_submitted_qc>March 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

